Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens' CEO, Rosalind Brewer, has left the company after only joining in 2021.

Walgreens CEO Steps Down In Surprise Management Shake-Up

On September 1, 2023, Walgreens Boots Alliance Inc ( WBA , Financial) made an unexpected announcement regarding the departure of Rosalind Brewer from her position as chief executive officer. This transition was portrayed as a mutual agreement between Brewer and the company.

Walgreens takes a Hit!

I have been bullish about Walgreens Boots Alliance for quite some time, nevertheless the stock continued to decline in the last few years. Not only were the last quarterly results a disappointment, but the company also lowered the guidance for fiscal 2023. When looking at the last few years, margins constantly declined and earnings per share as well as free cash flow are negative right now.

Walgreens Boots Alliance: Deeply Undervalued, But Declining Fundamentals

Airbnb

Deere & Company

Blackstone Group

Blackstone Inc. BX, -1.77% and Airbnb Inc. ABNB, +0.87% will join the S&P 500 index SPX, +0.18% before trading opens on Sept. 18, replacing Lincoln National Corp. LNC, +2.14% and Newell Brands Inc. NWL, +1.23%, S&P Dow Jones Indices said on Friday.

Airbnb, Blackstone to join S&P 500, while Deere will replace Walgreens in S&P 100

Walgreens Boots Alliance, Inc. is in disarray after CEO Rosalind Brewer stepped down, leaving the company without a full-time replacement for its top two executives. Under Brewer's leadership, WBA aggressively invested in its healthcare segment, acquiring medical groups and aiming to create an integrated healthcare-pharmacy services company. Despite growth in its healthcare segment, Walgreens has faced underperformance from VillageMD and CityMD, leading to a slower pace of clinic openings and a need to refocus growth plans.

Walgreens Is In Disarray As CEO Exits

Walgreens Boots Alliance (WBA) shares tumbled to levels not seen in almost a quarter century after the biggest U.S. pharmacy chain announced CEO Rosalind Brewer stepped down after less than three years at the helm.

Walgreens Shares Fall to Near 24-Year Lows After CEO Rosalind Brewer Steps Down

Ares Capital

Banco de Chile

British American Tobacco

Ecopetrol

Energy Transfer LP Unit

KeyCorp

MPLX

Annaly Capital

Petroleo Brasileiro

Stellantis N.V. 

AT&T

Telefonica SA

Vodafone Group

Western Gas Partners

Dogsofthedow.com recently published this list of 50 large-cap high-dividend stocks as of 8/31/23 per data from YCharts. The list targeted investors who “don't want to simply focus on a high dividend yield only to discover that the stock price has plunged or that the corporation went belly-up." Investors reduce volatility/risk by limiting high-dividend search to large-well-established companies.

50 Large-Cap High-Yield Stocks For September

CEO Rosalind Brewer is leaving after less than three years on the job. The company also said its fiscal 2023 earnings will come in at the bottom of the guidance range.

Why Walgreens Boots Alliance Stock Is Down Today

Rosalind Brewer was one of the few black CEOs among the Fortune 500 list of America's largest companies.

Walgreens shares tank after CEO Rosalind Brewer abruptly resigns

Roz Brewer has stepped down as the Chief Executive of Walgreens Boots Alliance Inc (NASDAQ: WBA). Shares of the retail pharmacy chain are down another 4.0% this morning.

Walgreens names industry veteran its interim CEO as Roz Brewer steps down

Rosalind Brewer has stepped down less than three years after taking the helm of the pharmacy operator.

Walgreens Chief Executive Steps Down

Walgreens CEO Rosalind Brewer is stepping down effectively immediately amid the drugstore giant's flagging share price and a multi-billion transformation to provide more healthcare services.

Roz Brewer Out As Walgreens CEO After Less Than Three Years

Walgreens Boots Alliance on Friday said that CEO Rosalind Brewer has stepped down less than three years after taking the helm at the pharmacy chain.

Walgreens CEO steps down

Rosalind Brewer was named chief executive officer of Walgreens in March 2021.

Walgreens Chief Executive Brewer Steps Down

Shares of Walgreens Boots Alliance Inc. WBA, -1.13% bounced 1.3% in premarket trading Friday, off the previous session's 14-year closing low, after the drugstore chain and health care services company said Chief Executive Rosalind Brewer has stepped down after 2 1/2-years in the role. The company has appointed Ginger Graham, the current lead independent director of Walgreen's board, as interim CEO.

Walgreens CEO Brewer steps down, and the stock bounces off 14-year low

Walgreens Boots Alliance said Friday that Roz Brewer had stepped down as the company's chief executive. She also left the company's board, effective Thursday. The decision was mutual, according to a news release.

Walgreens CEO Roz Brewer steps down after more than 2 years in the role

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance Announces Leadership Transition.

Walgreens Boots Alliance Announces Leadership Transition

Walgreens (WBA) is instructing Americans to administer this life-saving drug that, if given in time, can reverse the effects of an opioid overdose.

Walgreens (WBA) OTC NARCAN Nasal Spray to be Available Soon

Shares of Walgreens Boots Alliance Inc. WBA, +0.23% rose 0.4% in premarket trading Thursday, but were still headed for their worst monthly performance in more than four years. The drugstore chain and health care services company's stock has tumbled 14.6% in August through Wednesday, enough to make it by far the worst month-to-date performer in the Dow Jones Industrial Average DJIA, +0.11% ; the next worse is Goldman Sachs Group Inc.'s stock GS, -0.37%, which has lost 7.7% this month.

Walgreens stock heads for biggest monthly decline in more than 4 years

Online orders aren't cannibalizing store sales at Walgreens -- they are actually improving its growth rate. The retailer has been focusing on convenience by offering shoppers quick delivery and pickup options.

This Could Be an Underrated Growth Catalyst for Walgreens Boots Alliance

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is taking an important step to increase access to and education around naloxone by announcing that over-the-counter (OTC) NARCAN® Nasal Spray will be available at Walgreens stores and online as soon as Sept. 5, with nationwide availability on Sept. 7. This announcement follows the U.S. Food and Drug Administration's (FDA) approval earlier this year. This lifesaving medication can be used in the event of an opioid overdose to temporarily reverse the ef.

Walgreens Announces Over-the-Counter (OTC) NARCAN® Nasal Spray Will Become Available This September

Cincinnati Financial

Hormel Foods

Medtronic

Nordson

NextEra Energy

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

PPG Industries

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

The ProShares S&P 500 Dividend Aristocrat ETF started the second half of the year on a positive note, gaining 2.59% in July. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After two full years of tracking these strategies, only 1 strategy is beating NOBL, but all 3 continue to outpace SPY.

My Best Dividend Aristocrats For September 2023

Very rarely do investors get the opportunity to consider a purchase of a high-quality asset or company at a steep discount to the overall industry it operates within. Today, there is not only one name showcasing these symptoms, but two.

Does A 7.6% Dividend Make Walgreens A Better Buy Than CVS?

Altria

Truist Financial

Verizon

Investors love dividend stocks. They not only provide dependable income, but they also give investors a great opportunity for solid total return.

The 5 Highest-Yielding S&P 500 Stocks With Big Upside Potential and 7% or Higher Dividends

Crown Castle International

Dominion Energy

Huntington Bancshares

Lincoln National

What good is an S&P 500's company's plump dividend if its stock price collapses? Not much.

News for Walgreens Stock (WBA)